Table 1.
Baseline Characteristics of the Study Population
| Characteristics | pCR (n=24) | Non pCR (n=95) | P Value |
|---|---|---|---|
| Age (y) | |||
| ≤50 | 12 | 48 | 0.963 |
| >50 | 12 | 47 | |
|
Baseline maximum Tumor diameter (mm) | |||
| <20 | 0 | 2 | 0.592 |
| 20-50 | 16 | 51 | |
| >50 | 8 | 42 | |
| Clinical T stage | |||
| cT1 | 0 | 4 | 0.261 |
| cT2 | 14 | 38 | |
| cT3 | 5 | 36 | |
| cT4 | 5 | 17 | |
| Clinical N stage | |||
| cN0 | 0 | 0 | 0.062 |
| cN1 | 4 | 40 | |
| cN2 | 10 | 26 | |
| cN3 | 10 | 29 | |
| Receptor status | |||
| ER(+) | 7 | 67 | <0.001* |
| ER(-) | 17 | 28 | |
| PR(+) | 2 | 44 | <0.001* |
| PR(-) | 22 | 51 | |
| HER-2 | |||
| (+) | 11 | 40 | 0.742 |
| (-) | 13 | 55 | |
| Ki67% | |||
| ≤20% | 2 | 45 | <0.001* |
| >20% | 22 | 50 | |
| molecular subtypes | |||
| Luminal A | 0 | 11 | <0.001* |
| Luminal B1 | 1 | 37 | |
| Luminal B2 | 5 | 18 | |
| HER2 | 6 | 22 | |
| triple negative | 12 | 7 | |
| Menopausal status | |||
| Postmenopausal | 12 | 42 | 0.611 |
| Premenopausal | 12 | 53 | |
| Histological type | |||
| Invasive ductal carcinoma | 24 | 91 | 0.582 |
| Other | 0 | 4 | |
| Neoadjuvant treatment protocol | |||
| TC | 1 | 1 | 0.197 |
| FEC-T | 1 | 1 | |
| TEC | 18 | 82 | |
| EC-T | 3 | 10 | |
| Other | 1 | 1 | |
Note:*P value <0.05, indicating that the differences were considered statistically significant. Abbreviations: ER Estrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor type 2, T Docetaxel, C Cyclophosphamide, F 5-Fluorouracil, E Epirubicin